<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02080299</url>
  </required_header>
  <id_info>
    <org_study_id>135355-BO</org_study_id>
    <nct_id>NCT02080299</nct_id>
  </id_info>
  <brief_title>Protection by Remote Ischemic Preconditioning During Transcatheter Aortic Valve Implantation</brief_title>
  <official_title>Protection of Heart, Brain and Kidney by Remote Ischemic Preconditioning in Patients Undergoing Transcatheter Aortic Valve Implantation - a Randomized, Single-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Koblenz University of Applied Science</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcatheter aortic valve implantation (TAVI) has rapidly been adopted into clinical
      practice, but concerns have been raised regarding periprocedural complications like e.g.
      myocardial injury, stroke or acute kidney injury. Remote ischemic preconditioning (RIPC) with
      upper limb ischemia/reperfusion provides perioperative myocardial protection in patients
      undergoing elective coronary artery bypass surgery. The present study assesses protection of
      heart, brain and kidney by RIPC in patients undergoing TAVI. The study also addresses safety
      and clinical outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  On the assumption of our recent data (Thielmann et al, Lancet 2013, 382(9892):597-604),
           we performed a power analysis, revealing an estimated enrollment of 189 patients per
           group. But since no true data exist regarding RIPC and TAVI, interim analysis will be
           performed after 50 patients per group.

        -  After induction of conscious sedation or general anaesthesia, RIPC is accomplished by 3
           cycles of 5 min inflation/5 min deflation of a blood pressure cuff around the left arm
           to 200 mm Hg. In the placebo group, the blood pressure cuff remains uninflated for 30
           min.

        -  Blind: study coordinators, outcome assessors, operators and treating physicians except
           for the attending anaesthetist.

        -  Drugs used for conscious sedation: midazolam, remifentanil.

        -  Drugs used for general anaesthesia: sufentanil, etomidate, rocuronium, isoflurane.

        -  TAVI is performed by standard techniques using the balloon-expandable Sapien XT (Edwards
           Lifesciences Inc., Irvine, California, USA) and the next-generation Sapien 3 stent-valve
           bioprosthesis which replaces the Sapien XT prosthesis, when CE-approved.

        -  Arterial blood samples are obtained prior to and after RIPC-maneuver/Placebo, after
           aortic valve implantation and after access site closure, for biochemical analyses
           focussing on ligands that have been previously implicated in conditioning protocols at
           various organs. A bioassay system, consisting of a Langendorff-perfused isolated heart
           with ischemia and reperfusion will be used. This bioassay system will be exposed to the
           obtained arterial plasma of the patients.

        -  Venous blood samples are drawn before TAVI and at 1, 6, 12, 24, 48 and 72 hours after
           the procedure.

        -  Cardiac and cerebral MRI is performed in selected patients at baseline and within the
           first week after TAVI.

        -  On-site follow-up at 3±3 months, 12±3 months and yearly thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Extent of periinterventional myocardial injury as reflected by the geometric mean of the area under the curve (AUC) for troponin I serum concentrations</measure>
    <time_frame>72 hours postinterventionally after TAVI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Periprocedural myocardial infarction according to current Valve Academic Research Consortium (VARC-2) criteria</measure>
    <time_frame>72 hours postinterventionally after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new wall abnormalities and deterioration of overall left ventricular function as assessed by postinterventional transthoracic echocardiography</measure>
    <time_frame>Within the first week after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new-onset cardiac arrhythmias including the necessity of defibrillation or transient/permanent pacemaker implantation as assessed by continuous ECG-monitoring</measure>
    <time_frame>Within the first week after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence and volume of delayed gadolinium enhancement</measure>
    <time_frame>Within the first week after TAVI</time_frame>
    <description>Cardiac MRI will be performed in selected patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum elevation of serum creatinine concentration</measure>
    <time_frame>Until 72 hours after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum decrease of estimated glomerular filtration rate</measure>
    <time_frame>Until 72 hours after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of VARC-2 defined acute kidney injury</measure>
    <time_frame>Until 72 hours after TAVI and until discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total and median per patient number as well as total and median per patient volume of new foci of restricted diffusion</measure>
    <time_frame>Within the first week after TAVI</time_frame>
    <description>Cerebral MRI will be performed in selected patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardioprotective factor release into circulating blood</measure>
    <time_frame>Day of intervention</time_frame>
    <description>Blood samples will be collected at 4 time points: prior to and after RIPC-maneuver/Placebo, after aortic valve implantation and after access site closure. Time frame: approximately 2,5 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality and major adverse cardiac and cerebrovascular events (MACCE) at 30 days</measure>
    <time_frame>Within the first 30 days after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality and major adverse cardiac and cerebrovascular events (MACCE) at 1 year</measure>
    <time_frame>Within the first year after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality and major adverse cardiac and cerebrovascular events (MACCE) after 3 months</measure>
    <time_frame>Until 3 months after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VARC-2 defined combined early TAVI safety endpoint at 30 days</measure>
    <time_frame>Until 30 days after TAVI</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Remote ischemic preconditioning (RIPC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RIPC-protocol before TAVI: after induction of conscious sedation/anesthesia, but prior to TAVI procedure, remote ischemic preconditioning (RIPC) protocol is performed, consisting of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion, followed by a time interval between the end of the last deflation and local groin anaesthesia with subsequent skin puncture of 30 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo protocol before TAVI: After induction of conscious sedation/anesthesia and before TAVI, the cuff is left uninflated for 30 min, followed by a further time interval of 30 min until local groin anaesthesia with subsequent skin puncture.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Remote ischemic preconditioning (RIPC)</intervention_name>
    <description>3 circles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion, preceding TAVI procedure.</description>
    <arm_group_label>Remote ischemic preconditioning (RIPC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Prior to TAVI-procedure, the blood pressure cuff remains uninflated for 30 min.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with severe symptomatic native aortic valve stenosis scheduled for
             elective TAVI due to a prohibitive or high risk for surgical aortic valve replacement
             as judged by the institutional heart team based on risk scores and comorbidity
             assessment

          -  Written informed consent

        Exclusion Criteria:

          -  Life expectancy &lt; 1 year

          -  Patients who are unlikely to gain improvement in their quality of life by TAVI
             procedure

          -  Unfavorable anatomy for TAVI (e.g. inadequate annulus size)

          -  Left-ventricular thrombus

          -  Active endocarditis

          -  Active infection

          -  Acute ST-segment elevation myocardial infarction

          -  Hemodynamic instability

          -  Preoperative troponin I concentration above the upper normal limit of 0.1 ng/ml

          -  Stroke within the last 6 weeks

          -  Acute or chronic hemodialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Kahlert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, West-German Heart Center Essen, University Duisburg-Essen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthias Thielmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Thoracic and Cardiovascular Surgery, West-German Heart Center Essen, University Duisburg-Essen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Petra Kleinbongard, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Pathophysiology, University Duisburg-Essen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva Kottenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic for Anesthesiology and Intensive Care Medicine, University Duisburg-Essen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jürgen Peters, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic for Anesthesiology and Intensive Care Medicine, University Duisburg-Essen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heinz Jakob, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Thoracic and Cardiovascular Surgery, West-German Heart Center Essen, University Duisburg-Essen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raimund Erbel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, West-German Heart Center Essen, University Duisburg-Essen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerd Heusch, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Pathophysiology, University Duisburg-Essen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, West-German Heart Center Essen, University Duisburg-Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Thielmann M, Kottenberg E, Boengler K, Raffelsieper C, Neuhaeuser M, Peters J, Jakob H, Heusch G. Remote ischemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest. Basic Res Cardiol. 2010 Sep;105(5):657-64. doi: 10.1007/s00395-010-0104-5. Epub 2010 May 21.</citation>
    <PMID>20495811</PMID>
  </reference>
  <reference>
    <citation>Kottenberg E, Thielmann M, Bergmann L, Heine T, Jakob H, Heusch G, Peters J. Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol - a clinical trial. Acta Anaesthesiol Scand. 2012 Jan;56(1):30-8. doi: 10.1111/j.1399-6576.2011.02585.x. Epub 2011 Nov 21.</citation>
    <PMID>22103808</PMID>
  </reference>
  <reference>
    <citation>Heusch G, Musiolik J, Kottenberg E, Peters J, Jakob H, Thielmann M. STAT5 activation and cardioprotection by remote ischemic preconditioning in humans: short communication. Circ Res. 2012 Jan 6;110(1):111-5. doi: 10.1161/CIRCRESAHA.111.259556. Epub 2011 Nov 23.</citation>
    <PMID>22116817</PMID>
  </reference>
  <reference>
    <citation>Kottenberg E, Musiolik J, Thielmann M, Jakob H, Peters J, Heusch G. Interference of propofol with signal transducer and activator of transcription 5 activation and cardioprotection by remote ischemic preconditioning during coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2014 Jan;147(1):376-82. doi: 10.1016/j.jtcvs.2013.01.005. Epub 2013 Mar 1.</citation>
    <PMID>23465551</PMID>
  </reference>
  <reference>
    <citation>Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, Price V, Tsagakis K, Neuhäuser M, Peters J, Jakob H, Heusch G. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet. 2013 Aug 17;382(9892):597-604. doi: 10.1016/S0140-6736(13)61450-6. Erratum in: Lancet. 2013 Sep 14;382(9896):940.</citation>
    <PMID>23953384</PMID>
  </reference>
  <reference>
    <citation>Kleinbongard P, Thielmann M, Jakob H, Peters J, Heusch G, Kottenberg E. Nitroglycerin does not interfere with protection by remote ischemic preconditioning in patients with surgical coronary revascularization under isoflurane anesthesia. Cardiovasc Drugs Ther. 2013 Aug;27(4):359-61. doi: 10.1007/s10557-013-6451-3.</citation>
    <PMID>23440355</PMID>
  </reference>
  <reference>
    <citation>Kahlert P, Knipp SC, Schlamann M, Thielmann M, Al-Rashid F, Weber M, Johansson U, Wendt D, Jakob HG, Forsting M, Sack S, Erbel R, Eggebrecht H. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study. Circulation. 2010 Feb 23;121(7):870-8. doi: 10.1161/CIRCULATIONAHA.109.855866.</citation>
    <PMID>20177005</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2014</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2014</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Essen</investigator_affiliation>
    <investigator_full_name>Philipp Kahlert</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

